OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. George Discusses Next Steps in RCC

April 10th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses next steps for research in renal cell carcinoma (RCC).

Dr. Cerfolio on the Importance of Specialized Care in Lung Cancer

April 10th 2019

Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the importance of specialized care in lung cancer and sheds light on the current outlook of the disease.

Dr. Agarwal on Unmet Needs in mRCC

April 8th 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

Dr. Kim on Overcoming Resistance to TKIs in NSCLC

April 8th 2019

Chul Kim, MD, MPH, an attending physician at MedStar Health and an assistant professor of medicine at Georgetown University, discusses overcoming mechanisms of resistance to TKIs in non–small cell lung cancer (NSCLC).

Dr. Marshall on HER2 Amplification in Colorectal Cancer

April 8th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses HER2 amplification in colorectal cancer (CRC).

Dr. Kim on Role of Frontline Immunotherapy in Advanced HCC

April 8th 2019

Richard Kim, MD, assistant professor of oncology, University of South Florida College of Medicine, medical oncologist, Department of Gastrointestinal Oncology, Moffitt Cancer Center, discusses the role of frontline immunotherapy in patients with advanced hepatocellular carcinoma.

Dr. Raje on Treatment Approaches for Relapsed/Refractory Myeloma

April 8th 2019

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses treatment approaches for patients with relapsed/refractory multiple myeloma.

Dr. Bochner on Promising Targets and Pathways in Bladder Cancer

April 8th 2019

Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center, discusses promising targets and pathways in the treatment of patients with bladder cancer.

Dr. Trombetta on Recurrent NRG1 Rearrangements in Invasive Mucinous Adenocarcinoma

April 6th 2019

Domenico Trombetta, PhD, researcher, laboratory of oncology, Fondazione IRCCS Casa Sollievo della Sofferenza, discusses findings from an Italian multicenter cohort of patients with invasive mucinous adenocarcinoma, a rare histotype of lung adenocarcinoma.

Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

April 5th 2019

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Dr. Lossos on Research Questions in MCL

April 5th 2019

Izidore S. Lossos, MD, professor, director, Lymphoma Program Head of hematological malignancies site disease group, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses research questions in the field of mantle cell lymphoma (MCL).

Dr. Cohen on the Value of PFS as an Endpoint in Head and Neck Cancer

April 5th 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the value of progression-free survival (PFS) as an endpoint in head and neck cancer trials.

Dr. Kohman Discusses Importance of Lung Cancer Screening

April 5th 2019

Leslie J. Kohman, MD, FACS, Distinguished Service Professor of Surgery, Upstate University Hospital, Upstate Cancer Center, discusses the importance of lung cancer screening.

Dr. Lonial on Encouraging Data With Emerging Agents in Myeloma

April 5th 2019

Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in myeloma.

Dr. Johnson on Promise of Combination Therapy in Melanoma

April 5th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination therapy in patients with melanoma.

Dr. Dreicer on Biomarkers of Response to Immunotherapy in Urothelial Cancer

April 5th 2019

Robert Dreicer, MD, professor of medicine and urology, University of Virginia Health System, section chief, Medical Oncology, deputy director, UVA Cancer Center, discusses biomarkers of response to immunotherapy in patients with metastatic urothelial cancer.

Dr. Wallen on Surgery in Patients With Advanced Lung Cancer

April 4th 2019

Jason M. Wallen, MD, MBA, FACS, FCCP, associate professor of surgery, division chief of thoracic surgery, director of gastric and esophageal cancer program, medical director of the thoracic oncology program, Upstate University Hospital, discusses the role of surgery in patients with advanced-stage lung cancer.

Dr. Lee on Tailoring Treatment to Tumor Sidedness in mCRC

April 4th 2019

Michael S. Lee, MD, assistant professor of medicine, Department of Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment to tumor sidedness in patients with metastatic colorectal cancer.

Dr. Eber on Takeaways From the CARMENA Trial in mRCC

April 4th 2019

Paul R. Eber, MD, a urologist at Conrad-Pearson Clinic, discusses takeaways from the CARMENA trial in metastatic renal cell carcinoma (mRCC).

Dr. Shaughnessy Discusses Unanswered Questions in DLBCL

April 4th 2019

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses unanswered questions in the field of diffuse large B-cell lymphoma (DLBCL).